Ajinomoto — Company History

Ajinomoto’s origins reach back to 1888, when Suzuki Naka started an iodine-manufacturing family business in Hayama, Kanagawa. Under technical guidance from Nagai Nagayoshi, a professor at Tokyo Imperial University, the iodine trade grew into a pharmaceutical business and became the pillar that supported the Suzuki family — and, later, the capital base from which a wholly new venture was launched. In July 1908 Ikeda Kikunae, also of Tokyo Imperial University, patented a process for making the seasoning monosodium glutamate; that September the second Suzuki Saburosuke took on its commercialisation and became joint holder of the patent, running the existing iodine business in parallel to wall off the risk of an uncertain new business.

Household Aji-no-moto seasoning went on sale in May 1909. Trials at the Zushi works gave the family confidence in the process, and the Kawasaki plant was completed in September 1914, taking the business from cottage-scale work to modern mass production. From bases in Tokyo and Osaka it developed a regional sole-agent (tokuyakuten) system through the late 1910s and 1920s, layering sub-agents and retailers beneath each agent — a distinctive network that delivered price control and distribution control at the same time. By 1937 output reached 3,750 tonnes, the pre-war peak.

Kawasaki mass production joined to a national agent network left latecomers almost no way into the strong channels, and Ajinomoto’s dominance of the monosodium-glutamate market was fixed for decades, from the 1920s into the 1950s. Yet holding that network together required supplying more than a single condiment: agents needed a broader line of goods to carry, so the pull toward becoming a comprehensive foods company came as much from the distribution side as from technology. That double premise — a near-monopoly in seasoning, and a structural need to widen the product range — was carried, unresolved, into the decades that followed.

In 1956 Kyowa Hakko announced monosodium glutamate made by direct fermentation, and the extraction-method advantage that had underpinned Ajinomoto’s edge suddenly wavered. The trade press treated fermentation as an invention that overturned the old process, a view that Ajinomoto was heading into decline spread through the market, and the share price fell. Ajinomoto chose not to take the technical conflict to court: in November 1956 it contracted to buy Kyowa’s entire MSG output and so headed off the disruption. Ajinomoto also switched its own process, building a fermentation plant in Saga in 1962 and a synthesis plant at Yokkaichi in 1963 and converting Kawasaki away from extraction. The episode drove home how dangerous it was to depend on a single technology — and became the spark for diversification.

Aware now of how fragile an MSG-only earnings model was, Ajinomoto set out to widen its business and steady its returns. In 1963 an international tie-up with Corn Products of the United States created Knorr Foods, carrying Ajinomoto into processed foods on the back of soups, and an alliance pattern — an outside brand joined to Ajinomoto’s own channel — became its basic template. Management stated the task plainly: to turn a single-product Ajinomoto into a comprehensive foods company. From 1966 it added direct dealing with the fast-growing supermarkets alongside the agent system, and by 1970 the trade press was describing its ever-widening range as a “dinner-table encirclement.”

From the late 1950s Ajinomoto built plants overseas, starting in Southeast Asia: the Philippines in 1958, Thailand in 1960, Malaya in 1961, then Peru, Indonesia and Brazil. By 1977 it ran seven plants across Southeast Asia, South America and Europe, and income from overseas of about ¥2.5bn equalled 21.4 per cent of ordinary profit. Sales mix followed: seasonings were 52 per cent of ¥54.4bn in fiscal 1965, but by fiscal 1976 processed foods led with 28 per cent of ¥308.3bn. The comprehensive-foods result had limits, though: in 1983 MSG still held nearly 60 per cent of the domestic market, yet Ajinomoto’s profit growth since 1965 ranked near the bottom among major food firms, and by 1994 it trailed Kewpie in mayonnaise and Nisshin Oil in cooking oil, with no decisive top brand outside seasoning. Against that backdrop the most consequential move was a quiet one: in September 1998 Ajinomoto set up a specialist subsidiary and concentrated resources on ABF, an insulating film for semiconductor packaging derived from its amino-acid research, launching the world’s first film-type package-substrate insulator in 1999.

Scandal forced the governance question. Ajinomoto’s United States arm pleaded guilty in 1996 over a lysine price-fixing cartel and settled for a fine of about $10m, and in March 1997 a payments-to-racketeers (sokaiya) case broke, ending the presidency of Inamori Shunsuke — who had come back from group company Calpis only in June 1995 with a target of a 5 per cent return on equity. Four honorary chairmen and advisers still held sway over group appointments. His successor, Egashira Kunio, made “fair, impartial, transparent, simple” his watchwords, said plainly that “I decide everything now,” exited restaurants, hydroponics and golf courses, and put through 55 acquisitions and reorganisations in six years — among them spinning frozen foods out in 2000 and oils and fats in 2001, the step that led to the three-way edible-oil merger creating J-Oil Mills.

In 2003 Ajinomoto moved its oils-and-fats business into J-Oil Mills, formed by merging it with Honen Corporation and Yoshihara Oil Mill. The year before, the trade press had noted that the domestic food business — more than half of consolidated sales — was being squeezed as retail discounting became permanent, with a frozen-foods restructuring still unresolved on the books. The portfolio assembled in the name of comprehensive foods had turned into a drag on core earnings as retailers gained the upper hand on price, and it was no longer a problem Ajinomoto could solve by extending the same comprehensive-foods logic.

Faced with chronic low returns and oversupply in domestic oils, Ajinomoto chose horizontal integration as a means of exit — a rare manoeuvre in the food industry at the time — placing the business in a new company and withdrawing its own capital. Pulling invested capital out of a structurally low-return field and freeing it for redeployment was a genuine shift of thinking, and it later stood out in the company’s memory as the practical precedent for treating retreat as an ordinary tool. This experience became an important stepping-stone toward the capital-efficiency management Ajinomoto would adopt years later.

The strain did not ease. The feed-amino-acid business was moved to a dedicated group company in November 2011 as earnings fell; at home and abroad the group kept expanding by acquisition, taking in the United States frozen-foods maker Windsor Quality in November 2014 and a 33.33 per cent stake in Africa’s Promasidor Holdings in 2016. By November 2016 Ajinomoto had to cut its own guidance, and its operating margin of about 7 per cent stood against 15 per cent at Nestlé and 22 per cent at Kraft Heinz. The portfolio went on growing while the return on the capital tied up in it went, for the most part, unmeasured — the tension that the next decade would finally force into the open.

In the year ended March 2019 Ajinomoto booked impairment losses of about $286.2M (¥31bn), centred on its overseas food business. Consolidated sales rose while profit fell, and a structural problem surfaced in the numbers: through the 2010s capital had been allocated in favour of top-line growth without adequately verifying that the money invested was being earned back. It was a symbolic set of results — the negative side of comprehensive diversification concentrated into a single reckoning.

The response was a change of management system. In 2019 Ajinomoto placed ROIC at the centre of how it runs the company, calculating it business by business against the cost of capital and writing a rule into the organisation: being “technically right” or “socially meaningful” would no longer, on its own, justify holding capital in a business. Low-return units now had to answer on capital efficiency rather than future promise. That same year, though profitable, the company carried out 144 voluntary redundancies among managers aged 50 and over — institutionalising as routine what Japanese firms had long treated as a crisis measure, and signalling how far it meant to redesign its fixed-cost base.

The turns came quickly after that. In 2023 Ajinomoto scrapped its conventional three-year plan for “medium-term ASV management,” backcast from the company it wants to be in 2030, after president Taro Fujie diagnosed the old method as a “mid-plan disease”; it recast successive price increases as “value pricing,” an offensive strategy rather than a defensive one; and it stepped into gene-therapy contract manufacturing by acquiring the United States firm Forge Biologics for about $589.3M (¥83bn), choosing healthcare, under the banner of AminoScience, as a non-food earnings pillar to stand beside ABF. Yet the acquire-the-technology playbook stumbled early: Ajinomoto Althea, an earlier United States bio-pharma purchase, booked restructuring costs and an impairment. Whether Ajinomoto — which has swung its post-fermentation diversification from patient in-house cultivation to large acquisitions — can grow healthcare into a business to rival ABF is not yet clear.